title: The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+T cell responses.
abstract: Success in eliciting tumor rejection by therapeutic blockade of T cell checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4, has spurred re-evaluation of additional receptors that regulate antitumor responses. Here we summarize our recent studies characterizing the role of co-inhibitory receptor TIGIT in antitumor and other chronic CD8+T cell responses.
authors.affiliation: Department of Cancer Immunology; Genentech ; South San Francisco, CA, USA.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Johnston
authors.affiliation: Department of Cancer Immunology; Genentech ; South San Francisco, CA, USA.
authors.forename: Xin
authors.initials: X
authors.lastname: Yu
authors.affiliation: Department of Cancer Immunology; Genentech ; South San Francisco, CA, USA.
authors.forename: Jane L
authors.initials: JL
authors.lastname: Grogan
keywords: CD226; PD1; TIGIT; antibodies; cancer immunotherapy; virus